Vall d'Hebron Institut d'Oncologia - VHIO: Envíos recientes
Mostrando ítems 131-135 de 1251
-
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
(American Society of Clinical Oncology, 2025-04-20) -
AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular
(American Society of Hematology, 2025-01-14)



